Intercept Pharmaceuticals, Inc. (ICPT)
(Delayed Data from NSDQ)
$89.92 USD
+1.71 (1.94%)
Updated May 3, 2019 04:00 PM ET
After-Market: $89.98 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
[ICPT]
Reports for Purchase
Showing records 1 - 20 ( 867 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Intercept To Be Acquired by Alfasigma for $19 per Share in Cash; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
2Q23 Recap: Pivoting to ''Meaningful'' Profitability in 2024, While OCA+BZF on Track to Start Phase 3 Next Year, Too
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
There is Likely a Role for OCA-Beza FDC in PBC, Substantially Extending the Franchise; Double-Upgrade to Buy, $19 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
A Resounding Rebuke From the AdCom; Approval of OCA in NASH May Never Occur; Removing NASH From Our Model; DG to Sell
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
NDA Resubmission of OCA for Fibrotic NASH Sets in Motion a Potential PDUFA Date in Late August 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department